INT256006

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 10
Disease Relevance 2.61
Pain Relevance 0.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Lnpep) plasma membrane (Lnpep) intracellular (Lnpep)
cytoplasm (Lnpep)
Lnpep (Mus musculus)
Pain Link Frequency Relevance Heat
Eae 20 98.80 Very High Very High Very High
Onset of action 10 96.06 Very High Very High Very High
antagonist 60 94.52 High High
Enkephalin 10 91.92 High High
long-term potentiation 10 25.12 Quite Low
Hippocampus 30 23.84 Low Low
Thalamus 20 18.00 Low Low
Dopamine 20 14.16 Low Low
Locus ceruleus 10 7.12 Low Low
beta blocker 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cognitive Disorder 310 99.20 Very High Very High Very High
Sprains And Strains 80 86.40 High High
Obesity 10 81.92 Quite High
Targeted Disruption 20 68.16 Quite High
Aging 10 62.32 Quite High
Anxiety Disorder 20 14.80 Low Low
Hypertension 40 5.00 Very Low Very Low Very Low
Myocardial Infarction 10 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Wright and Harding [6], however, argue with equalled cogency that inhibition of IRAP cannot explain the cognitive effects of angiotensin IV.
Negative_regulation (inhibition) of IRAP associated with cognitive disorder
1) Confidence 0.48 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.23 Pain Relevance 0.13
Furthermore, it potentiated the contractile effects of oxytocin, suggesting inhibition of IRAP (oxytocinase) [33].
Negative_regulation (inhibition) of IRAP
2) Confidence 0.48 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.12 Pain Relevance 0.10
Furthermore, it potentiated the contractile effects of oxytocin, suggesting inhibition of IRAP (oxytocinase) [33].
Negative_regulation (inhibition) of oxytocinase
3) Confidence 0.48 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.13 Pain Relevance 0.10
Importantly, the mechanism of action of angiotensin IV remains unresolved, although inhibition of IRAP, and consequent increases in endogenous peptides such as oxytocin, currently seems unlikely.


Negative_regulation (inhibition) of IRAP
4) Confidence 0.36 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.64 Pain Relevance 0.04
The endogenous peptide LVV-Hemorphin-7, which is structurally unrelated to angiotensin IV but known to bind to AT4 receptors, inhibits the enzymatic activity of IRAP in vitro, similar to angiotensin IV.
Negative_regulation (inhibits) of IRAP
5) Confidence 0.36 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.08 Pain Relevance 0
The salient points of their argument are: the effects of enzyme inhibition and accumulation of endogenous peptides are slow, in the order of hours or days, whilst the onset of action of angiotensin IV in some tissues is within seconds; the concentrations of angiotensin IV required to produce biological, that is, cognitive effects, are well below the concentrations required to inhibit IRAP; and there is dispute as to whether angiotensin IV is a competitive substrate of IRAP or whether it binds allosterically.
Negative_regulation (inhibit) of IRAP associated with cognitive disorder and onset of action
6) Confidence 0.36 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.18 Pain Relevance 0.16
Our work, in combination with that of others, suggests that it is the peptide metabolites of oxytocin that are responsible for the enhanced cognition, and that angiotensin IV prevents its effects by inhibiting IRAP (oxytocinase) and the metabolism of oxytocin.
Negative_regulation (inhibiting) of oxytocinase associated with cognitive disorder
7) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.43 Pain Relevance 0.07
These results may be interpreted as an indication that by inhibiting IRAP (oxytocinase), angiotensin IV increases endogenous oxytocin to concentrations in the amnesic range, or that angiotensin IV blocks the behavioural effects of oxytocin by some other mechanism.
Negative_regulation (inhibiting) of IRAP
8) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.30 Pain Relevance 0.09
These results may be interpreted as an indication that by inhibiting IRAP (oxytocinase), angiotensin IV increases endogenous oxytocin to concentrations in the amnesic range, or that angiotensin IV blocks the behavioural effects of oxytocin by some other mechanism.
Negative_regulation (inhibiting) of oxytocinase
9) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.30 Pain Relevance 0.09
Some of these peptides, for example, oxytocin and vasopressin, have been implicated in learning and memory, and it also has been suggested by Albiston et al. [21], that inhibition of IRAP by angiotensin IV results in the accumulation of these peptides that enhance memory.
Negative_regulation (inhibition) of IRAP
10) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.20 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox